The Oral GLP-1 Pipeline: Amycretin and What's Coming After 2026
Key Takeaways
- Amycretin is a dual GLP-1/amylin receptor agonist — the first drug targeting both pathways simultaneously
- Phase 2 data showed up to ~13% weight loss at 12 weeks — an unprecedented rate of early weight loss
- Novo Nordisk is developing both oral and injectable formulations
- Phase 3 trials are underway — FDA approval is likely 2027 at the earliest
- If oral amycretin matches the Phase 2 data at scale, it could deliver 20%+ weight loss in pill form
Amycretin is the most closely-watched pipeline drug in obesity medicine, and for good reason. If the early clinical data holds up in Phase 3 trials, it could redefine what's possible with an oral weight-loss medication. Here's what we know, what we're waiting for, and why it matters.
Why Amycretin Is Different
Current GLP-1 medications target one receptor (GLP-1) or two (GLP-1 + GIP, as tirzepatide does). Amycretin targets GLP-1 and amylin receptors — a novel combination. Amylin is a hormone co-secreted with insulin from the pancreas that:
- Slows gastric emptying (complementing GLP-1's effect)
- Suppresses glucagon secretion
- Acts on the brain's area postrema to reduce appetite through a different pathway than GLP-1 alone
The hypothesis: targeting two appetite pathways simultaneously produces more weight loss than either pathway alone. The early data supports this.
The Phase 2 Data
Novo Nordisk published Phase 1/2 data showing:
| Metric | Amycretin (oral) | Oral Wegovy 25 mg (for context) |
|---|---|---|
| Weight loss at 12 weeks | ~13% | ~7% (OASIS data at similar timepoint) |
| Projected 52-week loss (extrapolated) | ~20–25% | ~15–17% |
| GI side effects | Common (nausea, vomiting) | Common (nausea, vomiting) |
| Sample size | Small (Phase 1/2) | Large (Phase 3) |
Phase 2 results from smaller trials don't always replicate in larger Phase 3 trials. The 52-week projection is extrapolated, not measured.
What's Next: Timeline
- 2025–2026: Phase 3 trials (REDEFINE program) enrolling and underway
- Late 2026–2027: Phase 3 readouts expected
- 2027–2028: FDA submission possible if Phase 3 data is strong
- 2028+: Potential commercial launch
Amycretin is not available for prescription. It exists only in clinical trials. Any website claiming to sell amycretin outside of an approved clinical trial is not legitimate. If you're interested in participating in a clinical trial, check ClinicalTrials.gov for enrolling studies.
What This Means for the Oral GLP-1 Market
If oral amycretin delivers 20%+ weight loss in Phase 3 — comparable to what the best injectable regimens currently achieve — it would eliminate the efficacy gap between oral and injectable obesity medications entirely. Currently, the best oral GLP-1 (oral Wegovy) delivers ~15–17%, while injectable combinations can reach 20–25%.
For the oral GLP-1 space, amycretin represents the next frontier: a pill that could match or exceed the best injection.
What's Available Now
While amycretin is years away, the current oral GLP-1 options already deliver meaningful weight loss:
Oral Wegovy (semaglutide)
FDA-ApprovedManufacturer: Novo Nordisk
Doses: 1.5 mg, 4 mg, 9 mg, 25 mg tablets
Pricing: List ~$1,350/mo · NovoCare self-pay $149 (1.5/4 mg) to $299 (9/25 mg) · Insurance + savings card $25/mo
Notes: FDA-approved for weight management. Must be taken on empty stomach with ≤4 oz water, 30 min before food/drink.
Learn more at NovoCare (manufacturer program — not an affiliate link)
Foundayo (orforglipron)
FDA-ApprovedManufacturer: Eli Lilly
Doses: Multiple dose strengths (titration schedule)
Pricing: Entry ~$149/mo · Maintenance ~$299–349/mo
Notes: FDA-approved April 1, 2026. First oral non-peptide GLP-1. No fasting requirement — can be taken with food.
Learn more at LillyDirect (manufacturer program — not an affiliate link)
Amycretin is the most promising oral obesity drug in the pipeline, with Phase 2 data suggesting it could deliver 20%+ weight loss as a pill. But it's years from availability. The current oral GLP-1 options — oral Wegovy and Foundayo — deliver 14–17% weight loss today, with compounded alternatives available at lower price points. Watch amycretin for the future; use what's available now.
Pipeline information based on publicly available clinical trial data and company disclosures. Drug development timelines are estimates and subject to change. This is not medical advice.